Effective and safe drug therapy in the treatment of Hp-associated diseases of the stomach and duodenum

Abstract

The introduction of potent antisecretory drugs and eradication therapy (ET) of Helicobacter pylori (HP) [1, 2] in the last decades of the XX century has dramatically changed the pathogenic concept of such HP-associated gastric diseases as chronic gastritis (CG) type B and duodenal ulcer disease (DUD), as well as their treatment. In the nearest future we are likely to witness further improvement of the therapeutic methods suggested in the twentieth century. [3, 4].